CN101331122B - Ppar调节剂的盐和治疗代谢性疾病的方法 - Google Patents

Ppar调节剂的盐和治疗代谢性疾病的方法 Download PDF

Info

Publication number
CN101331122B
CN101331122B CN2006800398402A CN200680039840A CN101331122B CN 101331122 B CN101331122 B CN 101331122B CN 2006800398402 A CN2006800398402 A CN 2006800398402A CN 200680039840 A CN200680039840 A CN 200680039840A CN 101331122 B CN101331122 B CN 101331122B
Authority
CN
China
Prior art keywords
ppar
compound
salt
group
term
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800398402A
Other languages
English (en)
Chinese (zh)
Other versions
CN101331122A (zh
Inventor
S·D·帕伦特
D·T·约奈蒂斯
D·A·贝内特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kelly Puxis
Original Assignee
Kelly Puxis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kelly Puxis filed Critical Kelly Puxis
Publication of CN101331122A publication Critical patent/CN101331122A/zh
Application granted granted Critical
Publication of CN101331122B publication Critical patent/CN101331122B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2006800398402A 2005-10-25 2006-10-23 Ppar调节剂的盐和治疗代谢性疾病的方法 Expired - Fee Related CN101331122B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73024905P 2005-10-25 2005-10-25
US60/730,249 2005-10-25
PCT/US2006/060172 WO2007051095A1 (en) 2005-10-25 2006-10-23 Salts of modulators of ppar and methods of treating metabolic disorders

Publications (2)

Publication Number Publication Date
CN101331122A CN101331122A (zh) 2008-12-24
CN101331122B true CN101331122B (zh) 2011-09-07

Family

ID=37770916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800398402A Expired - Fee Related CN101331122B (zh) 2005-10-25 2006-10-23 Ppar调节剂的盐和治疗代谢性疾病的方法

Country Status (14)

Country Link
US (1) US7863276B2 (https=)
EP (1) EP1940815B1 (https=)
JP (2) JP5322650B2 (https=)
KR (1) KR101464767B1 (https=)
CN (1) CN101331122B (https=)
AU (1) AU2006305769B2 (https=)
BR (1) BRPI0619282B8 (https=)
CA (1) CA2624383C (https=)
DK (1) DK1940815T3 (https=)
ES (1) ES2691548T3 (https=)
HU (1) HUE040020T2 (https=)
IL (1) IL190396A (https=)
NZ (1) NZ566831A (https=)
WO (1) WO2007051095A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007005205A (es) * 2004-10-29 2007-05-11 Kalypsys Inc Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
TW200745059A (en) * 2006-05-16 2007-12-16 Kalypsys Inc Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008091863A1 (en) * 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237130A (en) * 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
US4600709A (en) * 1982-10-22 1986-07-15 Ciba-Geigy Ag Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
CN85107226A (zh) * 1984-09-05 1987-04-08 盐野义制药株式会社 2，3-二氢苯并呋喃-5-磺酰胺衍生物的制备方法
CA1223874A (en) * 1982-10-22 1987-07-07 Paul Zbinden Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
CN1402712A (zh) * 1999-12-03 2003-03-12 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
WO2005016881A1 (de) * 2003-08-02 2005-02-24 Bayer Healthcare Ag Bicyclische indolinsulfonamid-derivate
WO2006055187A1 (en) * 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158596A3 (de) * 1984-04-06 1986-08-13 Ciba-Geigy Ag Neue substituierte Benzodioxolderivate, Verfahren zu deren Herstellung und entsprechende pharmazeutische Zusammensetzungen
JPS6163671A (ja) 1984-09-05 1986-04-01 Shionogi & Co Ltd ２，３−ジヒドロベンゾフラン−５−スルホンアミド誘導体および降圧利尿剤
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
PE86199A1 (es) 1997-06-17 1999-09-24 Schering Corp Sulfonamida inhibidor de la enzima farnesilo transferasa
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
ES2300151T3 (es) 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
WO2000056704A1 (en) 1999-03-22 2000-09-28 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
GB0007907D0 (en) 2000-03-31 2000-05-17 Merck Sharp & Dohme Therapeutic agents
CA2423744C (en) 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
WO2002051836A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
IL158590A0 (en) 2001-06-11 2004-05-12 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
CA2479906C (en) 2002-04-03 2011-02-08 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
EP1511488B1 (en) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Human adam-10 inhibitors
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物
US20070208026A1 (en) 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
KR100762762B1 (ko) 2003-04-17 2007-10-17 칼립시스, 인코포레이티드 Ｐｐａｒ의 조절인자로서의 아릴 화합물 및 신진대사장애의 치료 방법
MXPA06001202A (es) 2003-07-29 2006-08-31 Xenon Pharmaceuticals Inc Derivados piridilo y su uso como agentes terapeuticos.
KR20060036106A (ko) 2003-07-30 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
CN1829701A (zh) 2003-07-30 2006-09-06 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
CN101712653A (zh) 2003-07-30 2010-05-26 泽农医药公司 哒嗪衍生物和它们作为治疗剂的用途
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005060958A1 (en) 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
CA2573198A1 (en) 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
JP5080256B2 (ja) 2004-09-20 2012-11-21 ゼノン・ファーマシューティカルズ・インコーポレイテッド 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP1827438B2 (en) 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
US20070190079A1 (en) 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
WO2007047432A1 (en) 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonamide derivatives as modulators of ppar
US20090143396A1 (en) 2005-10-12 2009-06-04 Malecha James W Sulfonyl-Substituted Aryl Compounds as Modulators of Peroxisome Proliferator Activated Receptors
EP1996198A1 (en) 2006-03-17 2008-12-03 Kalypsys, Inc. Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar
US20070249519A1 (en) 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
US20080004281A1 (en) 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
US20080287477A1 (en) 2006-10-11 2008-11-20 Kalypsys, Inc. Novel Compounds as Modulators of Ppar
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237130A (en) * 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
US4600709A (en) * 1982-10-22 1986-07-15 Ciba-Geigy Ag Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
CA1223874A (en) * 1982-10-22 1987-07-07 Paul Zbinden Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
CN85107226A (zh) * 1984-09-05 1987-04-08 盐野义制药株式会社 2，3-二氢苯并呋喃-5-磺酰胺衍生物的制备方法
CN1402712A (zh) * 1999-12-03 2003-03-12 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
WO2005016881A1 (de) * 2003-08-02 2005-02-24 Bayer Healthcare Ag Bicyclische indolinsulfonamid-derivate
WO2006055187A1 (en) * 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar

Also Published As

Publication number Publication date
BRPI0619282A2 (pt) 2011-09-20
NZ566831A (en) 2011-09-30
ES2691548T3 (es) 2018-11-27
EP1940815B1 (en) 2018-08-15
WO2007051095A1 (en) 2007-05-03
JP5322650B2 (ja) 2013-10-23
DK1940815T3 (en) 2018-11-05
KR20080059575A (ko) 2008-06-30
IL190396A0 (en) 2008-11-03
EP1940815A1 (en) 2008-07-09
KR101464767B1 (ko) 2014-11-24
IL190396A (en) 2017-09-28
US20070093504A1 (en) 2007-04-26
BRPI0619282B1 (pt) 2021-05-04
CN101331122A (zh) 2008-12-24
JP2009513679A (ja) 2009-04-02
AU2006305769B2 (en) 2012-06-14
JP2013166788A (ja) 2013-08-29
CA2624383C (en) 2014-03-11
HUE040020T2 (hu) 2019-02-28
US7863276B2 (en) 2011-01-04
BRPI0619282B8 (pt) 2021-05-25
AU2006305769A1 (en) 2007-05-03
CA2624383A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
CA2465326C (en) Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel
TWI304062B (en) N-(pyridin-2-yl)-sulfonamide derivatives
RU2706007C2 (ru) Конденсированные бициклические соединения для лечения заболевания
WO2001083427A1 (en) PPARη MODULATORS
KR20010113972A (ko) 융합 복소환 화합물의 염산염
CN105121423A (zh) 新型3-(4-(苄氧基)苯基)己-4-炔酸衍生物、其制备方法、和包括其作为有效成分的用于预防和治疗代谢性疾病的药物组合物
CN101331122B (zh) Ppar调节剂的盐和治疗代谢性疾病的方法
JP2511204B2 (ja) 置換インド―ル
CN107602523A (zh) 京尼平类似物、制备方法及其应用
CN101397300B (zh) 二肽酶-ⅳ抑制剂衍生物
JP5102849B2 (ja) Ｎ−ヒドロキシ−４−｛５−［４−（５−イソプロピル−２−メチル−１，３−チアゾール−４−イル）フェノキシ］ペントキシ｝ベンズアミジン２エタンスルホン酸塩、その製造方法およびそれを含む薬学組成物
TW201717956A (zh) 羥基嘌呤類化合物的醫藥用途
TW202421620A (zh) 馬拉利習巴(maralixibat)固體形式、中間體及其製備方法
KR20230121762A (ko) (5s)-사이클로프로필-5-[3-[(3s)-4-(3,5-디플루오로페닐)-3-메틸-피페라진-1-일]-3-옥소-프로필]이미다졸리딘-2,4-디온의 고체 형태
WO2024027751A1 (zh) 一种杂环化合物的晶型、其制备方法及其应用
TW202543619A (zh) Ｒｘｆｐ１受體促效劑
KR20250065708A (ko) 타우 응집 억제제
CN116723840A (zh) (5s)-环丙基-5-[3-[(3s)-4-(3,5-二氟苯基)-3-甲基-哌嗪-1-基]-3-氧代-丙基]咪唑烷-2,4-二酮的固体形式
WO2021023119A1 (zh) 美利曲辛与氟哌噻吨共晶及其制备方法
CN102076682A (zh) 五元环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110907

CF01 Termination of patent right due to non-payment of annual fee